Fatigue Prognostic for Survival in Certain Patients With Myelodysplastic Syndromes
the ONA take:
Self-reported fatigue severity provides prognostic information for survival independent from gold-standard risk classifications in patients with newly diagnosed higher-risk myelodysplastic syndromes, a new study published online ahead of print in the journal The Lancet Oncology has shown.
Because the clinical presentation of myelodysplastic syndromes can be highly variable, researchers sought to evaluate whether self-reported fatigue severity is prognostic for overall survival in higher-risk patients.
For the study, researchers enrolled 280 patients with myelodysplastic syndromes who were enrolled within 6 months of diagnosis with an intermediate-2-risk or high-risk score.
Results showed that the median overall survival from diagnosis was 17 months. Researchers found that high-risk International Prognostic Scoring System (IPSS) score and a higher score for fatigue were independently associated with reduced overall survival. Self-reported fatigue remained a statistically significant prognostic factor for survival in further multivariate analyses.
“Our findings suggest that fatigue assessment should be included in routine diagnostic investigation for these patients and considered as a standard baseline stratification factor in future randomized controlled trials,” the authors conclude.
Self-reported fatigue severity provides prognostic information for newly diagnosed higher-risk myelodysplastic syndromes.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|